Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2019-01-30 Earnings Release
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
Earnings Release Classification · 100% confidence The document is a detailed financial results announcement for Novartis for the full year and fourth quarter of 2018. It contains key financial metrics (net sales, operating income, net income, EPS, free cash flow), divisional performance breakdowns (Innovative Medicines, Sandoz, Alcon), and strategic updates. While it is a comprehensive summary of financial results, it is structured as an initial earnings release (highlighting key figures and management commentary) rather than a full statutory annual report or a quarterly financial statement filing. Therefore, it is classified as an Earnings Release. FY 2018
2019-01-30 English
FORM 6-K
Regulatory Filings
2018-12-21 English
Novartis successfully completes acquisition of Endocyte
M&A Activity Classification · 98% confidence The document is titled 'NOVARTIS FINANCE S.A. / Novartis successfully completes acquisition of Endocyte' and is dated December 21, 2018. It details the completion of a corporate transaction (acquisition) and includes standard press release elements like forward-looking statements, boilerplate 'About Novartis' information, and contact details for Media and Investor Relations. This format strongly suggests a corporate news announcement, typically distributed via a wire service (like Globenewswire mentioned in the source line). Since the content is a specific corporate action announcement (M&A completion) and not a general regulatory filing, it fits best under the category for M&A Activity (TAR) or potentially a general Regulatory Filing (RNS) if TAR was not available. Given the explicit focus on the acquisition completion, TAR is the most precise fit. It is not an ER (Earnings Release), IR (Interim Report), or 10-K (Annual Report).
2018-12-21 English
FORM 6-K
Regulatory Filings
2018-12-20 English
Novartis announces new CEO of Oncology Business Unit
Board/Management Information Classification · 98% confidence The document is a press release from Novartis announcing a change in senior management: the appointment of a new CEO for the Oncology Business Unit and the stepping down of the previous CEO. This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management. It is not a full financial report (10-K or IR), an earnings release (ER), or a transcript (CT).
2018-12-20 English
FORM 6-K
Regulatory Filings
2018-11-14 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.